Abstract 12443: In-Beam PET Verification of Catheter-free Arrhythmia Ablation by Scanned Carbon-12 Ion Beam Irradiation
Introduction: Highly precise irradiation using carbon-12 (12C) ions is a new means for catheter-free ablation. Besides energy deposition leading to the dose distribution, nuclear interactions lead to by-product β+-activity that can be measured using positron-emission-tomography (PET).
Hypothesis: In-beam PET scanning during focused myocardial irradiation using 12C can adequately depict 12C dose deposition.
Methods: Pigs were irradiated with 25, 40, and 55 Gy for AV node (AVN), LA-PV junction, and local LV freewall ablations. PET measurement was performed by means of a double head camera system installed at irradiation site. Coincidences were captured in end-expiration during beam extraction pauses of the accelerator.
Results: Evaluation of PET images was qualitatively performed using the coronal plane of the activity distribution superimposed on the contrast-CT in the center of the target contour. Strong β+-activities were measured in AVN and LV ablations. In AVN ablations, activity was localized to the target location, without target activity spreading to the level of the aortic root or coronary sinus (Figure A). Local LV irradiations revealed strong activity in the target location, slightly extending into left lung and chest wall (Figure B). In 55 Gy animals, the cardiac entry channel showed increased activity, decreasing in 40 Gy and more so in 25 Gy animals.
Conclusion: This is the first study applying in-beam PET to track 12C dose-deposition into the target location for catheter-free ablation in intact animals. Correlation of β+-activity to electrophysiological outcome, lesion induction, and potential side-effects may be critically important in dosing therapy and predicting outcomes.
Author Disclosures: H. Lehmann: None. F. Fiedler: None. S. Helmbrecht: None. C. Graeff: None. A. Constantinescu: None. P. Lugenbiel: None. M. Prall: None. R. Kaderka: None. M. Takami: None. D. Richter: None. A. Eichhorn: None. D. Thomas: None. H. Katus: None. S. Johnson: None. K. Parker: None. J. Debus: None. S. Asirvatham: Consultant/Advisory Board; Modest; Abiomed, Atricure, Biotronik, Biosense Webster, Boston Scientific, Medtronic, Spectranetics, St. Jude, Sanofi-aventis, Wolters Kluwer, Elsevier. C. bert: None. M. Durante: None. D.L. Packer: Research Grant; Modest; Endosense, EP Advocate, CardioFocus, Hansen Medical, Siemens Acuson, Thermedical (EP Limited), CardioInsight. Research Grant; Significant; American Heart Association, Biosense Webster, Boston Scientific/EPT, EPiEP, Medtronic, NIH, St. Jude Medical. Consultant/Advisory Board; Modest; Abiomed $0, Biosense Webster $0, Boston Scientific $0, CardioDX $0, CardioFocus $0, CardioInsight Technologies $0, Excerpta Medica $0, FoxP2 Medica LLC $0, InfoBionic Inc. $0, Johnson & Johnson Healthcare Systems $0, Johnson & Johnson $0, MediaSphere Medical LLC $0, Medtronic CryoCath $0, OrthoMcNeill $0, Sanofi-aventis $0, Siemens $0, St. Jude Medical $0, Siemens AG $0. Other; Modest; Blackwell Publishing, Oxford Royalty. Other; Significant; St. Jude Medical.
- © 2015 by American Heart Association, Inc.